IMV Inc.

IMV Inc.

IMVIQ
IMV Inc.US flagOther OTC
0.00
USD
+0.00
- -
117.00Market Cap
No data availableFinancial data will appear here once available

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

APIChat
CEO
Andrew Hall
Full Time Employees
63
Sector
Healthcare
Industry
Biotechnology
Address
130 Eileen Stubbs Avenue Dartmouth NS Canada B3B 2C4
IPO Date
Oct 9, 2009
Business
IMV Inc. (IMVIQ) is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies using its proprietary DPX platform technology. The company offers a pipeline of product candidates including DPX-Survivac, an immunotherapy targeting survivin-expressing cancer cells for indications such as ovarian cancer and lymphoma; DPX-PDV, a preventive vaccine against human papillomavirus; and other investigational therapies leveraging the DPX delivery system for antigen-specific immune responses, which encapsulates antigens and adjuvants to achieve prolonged T-cell activation with minimal dosing requirements. IMV provides research and development services in immunotherapy formulation and immune response modulation, targeting oncologists, hospitals, and biotech partners in the immuno-oncology segment. Founded in 2000 and headquartered in Dartmouth, Nova Scotia, Canada, with additional operations in the United States and Europe, IMV serves global markets in North America, Europe, and Asia-Pacific through clinical trials and strategic collaborations. The company operates in the biotechnology industry, with business segments centered on immuno-oncology therapeutics and vaccine delivery technologies, catering primarily to patients with advanced solid tumors and hematological malignancies via partnerships with pharmaceutical firms. In the last two years, IMV has undergone significant changes including a ticker symbol update to IMVIQ reflecting its Nasdaq listing status amid strategic restructuring; completion of a reverse stock split and ongoing efforts to regain compliance with exchange requirements following financial challenges; advancement of DPX-Survivac into combination trials with checkpoint inhibitors like pembrolizumab, reporting promising phase 2 data in 2024 for platinum-resistant ovarian cancer; and formation of alliances with entities such as Merck for clinical development support, alongside cost-optimization measures including workforce reductions to extend cash runway into 2026. These developments underscore IMV's shift toward leaner operations and focused pipeline prioritization amid a challenging biotech funding environment.

Company News

APIChat
  • Whitehawk Therapeutics (NASDAQ:WHWK) versus IMV (OTCMKTS:IMVIQ) Financial Review

  • Critical Comparison: NexImmune (NASDAQ:NEXI) vs. IMV (OTCMKTS:IMVIQ)